Last reviewed · How we verify
LY03020
At a glance
| Generic name | LY03020 |
|---|---|
| Also known as | LPM787000048 Maleate sustained-release tablet |
| Sponsor | Luye Pharma Group Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia (PHASE2)
- A Food Effect Study of LY03020 in Healthy Subjects (PHASE1)
- A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020 (PHASE1)
- A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY03020 CI brief — competitive landscape report
- LY03020 updates RSS · CI watch RSS
- Luye Pharma Group Ltd. portfolio CI